Osteoprotegerin prevents and reverses hypercalcemia in a murine model of humoral hypercalcemia of malignancy

Cancer Research

Volumn 60, Issue 4, 2000, Pages 783-787

  Capparelli, Casey ^a   Kostenuik, Paul J ^a   Morony, Sean ^a   Starnes, Charlie ^b   Weimann, Bernadette ^b   Van, Gwyneth ^a   Scully, Sheila ^a   Qi, Meiying ^a   Lacey, David L ^a   Dunstan, Colin R ^a,b  

^a Department of Pathology ^*  (United States)

^b AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; OSTEOPROTEGERIN; PARATHYROID HORMONE DERIVATIVE; TUMOR NECROSIS FACTOR RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CALCIUM BLOOD LEVEL; COLON TUMOR; CONTROLLED STUDY; DRUG POTENCY; DRUG TOLERABILITY; HYPERCALCEMIA; MALE; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; GLYCOPROTEINS; HYPERCALCEMIA; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED DBA; NEOPLASMS, EXPERIMENTAL; OSTEOCLASTS; OSTEOPROTEGERIN; PARATHYROID HORMONE-RELATED PROTEIN; PROTEINS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR;

EID: 0034652458     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Stewart, A. F. Humoral hypercalcemia of malignancy. In: M. J. Favus (ed.), Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, Ed. 3, pp. 198-203. Philadelphia: Lippincott-Raven, 1996.
2. Wysolmerski, J. L., and Broadus, A. E. Hypercalcemia of malignancy: the central role of parathyroid hormone related protein. Annu. Rev. Med., 45: 189-200, 1994.
3. Strewler, G. J., Stern, P. H., Jacobs, J. W., Eveloff, J., Klein, R. F., Leung, S. C., Rossenblatt, M., and Nissenson, R. A. Parathyroid hormone-like protein from human renal carcinoma cells. Structural and functional homology with parathyroid hormone. J. Clin. Investig., 80: 1803-1807, 1987.
4. Moseley, J. M., Kubota, M., Diefenbach-Jagger, H., Wettenhall, R. E. H., Kemp, B. E., Suva, L. J., Rodda, C. P., Ebeling, P. R., Hudson, P. J., Zajac, J. D., and Martin, T. J. Parathyroid hormone-related protein purified from a human lung cancer cell Line. Proc. Natl. Acad. Sci. USA, 84: 5048-5052, 1987.
5. Burtis, W. J., Wu, T., Bunch, C., Wysolmerski, J. J., Insogna, K. L., Weir, E. C., Broadus, A. E., and Stewart, A. F. Identification of a novel 17,000-dalton parathyroid hormone-like adenylate cyclase-stimulating protein from a tumor associated with humoral hypercalcemia of malignancy. J. Biol. Chem., 262: 7151-7156, 1987.
6. Gurney, H., Grill, V., and Martin, T. J. Parathyroid hormone-related protein and response to pamidronate in tumour-induced hypercalcaemia. Lancet, 341: 1611-1613, 1993.
7. Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M. S., Luethy, R., Nguyen, H. Q., Wooden, S., Bennett, L., Boone, T., Shimamoto, G., DeRose, M., Elliott, R., Colombero, A., Tan, H. L., Trail, G., Sullivan, J., Davy, E., Bucay, N., Renshaw-Gegg, L., Hughes, T. M., Hill, D., Pattison, W., Campbell, P., Sander, S., Van, G., Tarpley, J., Derby, P., Lee, R., and Boyle, W. J. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell, 2: 309-319, 1997.
8. Tsuda, E., Goto, M., Mochizuki, S., Yano, K., Kobayashi, F., Morinaga, T., and Higashio, K. Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochem. Biophys. Res. Commun., 234: 137-142, 1997.
9. Bucay, N., Sarosi, I., Dunstan, C. R., Morony, S., Tarpley, J., Capparelli, C., Scully, S., Tan, H. L., Xu, W. L., Lacey, D. L., Boyle, W. J., and Simonet, W. S. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev., 12: 1260-1268, 1998.
10. Lacey, D. L., Timms, E., Tan, H. L., Kelley, M. J., Dunstan, C. R., Burgess, T., Elliott, R., Colombero, A., Elliott, G., Scully, S., Hsu, H., Sullivan, J., Hawkins, N., Davy, E., Capparelli, C., Eli, A., Qian, Y. X., Kaufman, S., Sarosi, I., Shalhoub, V., Senaldi, G., Guo, J., Delaney, J., and Boyle, W. J. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell, 93: 165-176, 1998.
11. Kong, Y. Y., Yoshida, H., Sarosi, I., Tan, H. L., Timms, E., Capparelli, C., Morony, S., Oliveira-dos-Santos, A. J., Van, G., Itie, A., Khoo, W., Wakeham, A., Dunstan, C. R., Lacey, D. L., Mak, T. W., Boyle, W. J., and Penninger, J. M. OPGL is a key regulator of osteoclastogenesis, lymphocyte development, and lymph-node organogenesis. Nature (Lond.), 397: 315-323, 1999.
12. Yasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Mochizuki, S., Tomoyasu, A., Yano, K., Goto, M., Murakami, A., Tsuda, E., Morinaga, T., Higashio, K., Udagawa, N., Takahashi, N., and Suda, T. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl. Acad. Sci. USA, 95: 3597-3602, 1998.
13. Lee, S. K., and Lorenzo, J. A. Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formation. Endocrinology, 140: 3552-3561, 1999.
14. 3. J. Bone. Miner. Res., 14: 1478-1485, 1999.
15. Corbett, T. H., Griswold, D. P., Jr., Roberts, B. J., Peckham, J. C., and Schabel, F. M., Jr. Tumor induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assays, with a note on carcinogen structure. Cancer Res., 35: 2434-2439, 1975.
16. Fujita, J., Tsujinaka, T., Yano, M., Ebisui, C., Saito, H., Katsume, A., Akamatsu, K., Ohsugi, Y., Shiozaki, H., and Monden, M. Anti-interleukin-6 receptor antibody prevents muscle atrophy in colon-26 adenocarcinoma-bearing mice with modulation of lysosomal and ATP-ubiquitin-dependent proteolytic pathways. Int. J. Cancer, 68: 637-643, 1996.
17. Strassmann, G., Fong, M., Kenney, J. S., and Jacob, C. O. Evidence for the involvement of interleukin 6 in experimental cancer cachexia. J. Clin. Investig., 89: 1681-1684, 1992.
18. Strassmann, G., Jacob, C. O., Fong, M., and Bertolini, D. R. Mechanisms of paraneoplastic syndromes of colon-26: involvement of interleukin 6 in hypercalcemia. Cytokine, 463-468, 1993.
19. Faust, J., Lacey, D. L., Hunt, P., Burgess, T. L., Scully, S., Van, G., Eli, A., Qian, Y. X., and Shalhoub, V. Osteoclast markers accumulate on cells developing from human peripheral blood mononuclear precursors. J. Cell. Biochem., 72: 67-80, 1999.
20. Jimi, E., Akiyama, S., Tsurukai, T., Okahashi, N., Kobayashi, K., Udagawa, N., Nishihara, T., Takahashi, N., and Suda, T. Osteoclast differentiation factor acts as a multifunctional regulator in murine osteoclast differentiation and function. J. Immunol., 163: 434-442, 1999.
21. Fuller, K., Wong, B., Fox, S., Choi, Y., and Chambers, T. J. TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts. J. Exp. Med., 188: 997-1001, 1998.
22. Shalhoub, V., Faust, J., Boyle, W. J., Dunstan, C. R., Kelley, M., Kaufman, S., Scully, S., Van, G., and Lacey, D. L. Osteoprotegerin and osteoprotegerin ligand effects on osteoclast formation from human peripheral blood mononuclear cell precursors. J. Cell. Biochem., 72: 251-261, 1999.
23. Burgess, T. L., Qian, Y., Kaufman, S., Ring, B. D., Van, G., Capparelli, C., Kelley, M., Hsu, H., Boyle, W. J., Dunstan, C. R., Hu, S., and Lacey, D. L. The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J. Cell. Biol., 145: 527-538, 1999.
24. Akatsu, T., Murakami, T., Nishikawa, M., Ono, K., Shinomiya, N., Tsuda, E., Mochizuki, S., Yamaguchi, K., Kinosaki, M., Higashio, K., Yamamoto, M., Motoyoshi, K., and Nagata, N. Osteoclastogenesis inhibitory factor suppresses osteoclast survival by interfering in the interaction of stromal cells with osteoclast. Biochem. Biophys. Res. Commun., 250: 229-234, 1998.
25. Rizzoli, R., Caverzasio, J., Chapuy, M. C., Martin, T. J., and Bonjour, J. P. Role of bone and kidney in parathyroid hormone-related peptide-induced hypercalcemia in rats. J. Bone Miner. Res., 4: 759-765, 1989.
26. De la mata, J., Uy, H. L., Guise, T. A., Story, B., Boyce, B. F., Mundy, G. R., and Roodman, G. D. Interleukin-6 enhances hypercalcemia and bone resorption mediated by parathyroid hormone-related protein in vivo. J. Clin. Investig., 95: 2846-2852, 1995.
27. Bekker, P., Holloway, D., Nakanishi, A., Arrighi, H., and Dunstan, C. Osteoprotegerin (OPG) has potent and sustained anti-resorptive activity in postmenopausal women. J. Bone Miner. Res., 14 (Suppl. 1): S180, 1999.
28. vanBreukelen, F., Bijvoet, O., Frijlink, W., Sleeboom, H., Mulder, H., and vanOosterom, A. Efficacy of amino-hydroxypropylidene bisphosphonate in hypercalcemia: observations on regulation of serum calcium. Calcif. Tissue Int., 34: 321-327, 1982.
29. Capparelli, C., Kostenuik, P., Morony, S., Stames, C., Weimann, B., Sarosi, I., Lacey, D. L., and Dunstan, C. R. Comparison of osteoprotegerin and pamidronate in a murine model of humoral hypercalcemia of malignancy. J. Bone Miner. Res., 14 (Suppl. 1): S163, 1999.